Comparing Repotrectinib vs Rybrevant
| Repotrectinib | Rybrevant (amivantamab) |
|
|---|
| Repotrectinib | Rybrevant (amivantamab) |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Non Small Cell Lung Cancer, Solid Tumors. Repotrectinib may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Non Small Cell Lung Cancer. Rybrevant may also be used for purposes not listed in this medication guide. |
||||||||
| More about Repotrectinib | More about Rybrevant (amivantamab) | ||||||||
| Ratings & Reviews | |||||||||
|
Be the first to share your experience with this drug. |
Rybrevant has an average rating of 8.5 out of 10 from a total of 4 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||
|
View all Repotrectinib side effects |
View all Rybrevant side effects |
||||||||
| Drug Class | |||||||||
| Generic Availability | |||||||||
|
N/A |
N/A |
||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Rybrevant prices |
||||||||
| Dosage Forms | |||||||||
|
N/A |
|
||||||||
| Brand Names | |||||||||
| Augtyro |
N/A |
||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||
|
50.6 hours |
271.2 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | |||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||
| Drug Interactions | |||||||||
|
A total of 574 drugs are known to interact with Repotrectinib:
|
A total of 18 drugs are known to interact with Rybrevant:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
| Disease Interactions | |||||||||
|
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|||||||||
| First Approval Date | |||||||||
|
November 15, 2023 |
N/A |
||||||||
| WADA Class View classifications | |||||||||
|
N/A |
N/A |
||||||||
| More Information | |||||||||
| Patient Resources | |||||||||
| Professional Resources | |||||||||
| Related Treatment Guide | |||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Opdivo Qvantig
Opdivo Qvantig is used to treat adults with melanoma, non-small cell lung cancer, renal cell ...
Rybrevant
Rybrevant is used to treat certain types of non-small cell lung cancer (NSCLC) in adults. It is ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Keytruda
Keytruda is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma ...
Avastin
Avastin is used to brain tumors and cancers of the kidney, colon, rectum, or lung. Learn about side ...
Tagrisso
Tagrisso (osimertinib) may be used to treat adults with non-small cell lung cancer (NSCLC) whose ...
Docetaxel
Docetaxel is used for breast cancer, breast cancer, metastatic, gastric cancer, head and neck ...
Nivolumab
Nivolumab is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma ...
Paclitaxel
Paclitaxel is used for breast cancer, breast cancer, adjuvant, breast cancer, metastatic, kaposi's ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.